Data from Pharmawand - Curated by EPG Health - Date added 01 September 2018
AstraZeneca and MedImmune, announced top-line results from the from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant reduction in disease activity in patients with SLE as measured by the SLE Responder Index 4 (SRI4) at 12 months.
The pivotal Phase III TULIP 1 trial was a randomised, double-blinded, 52-week placebo-controlled, multi-centre trial assessing the safety and efficacy of anifrolumab as a treatment for adult patients with moderate-to-severe SLE. A full evaluation of the data will be conducted when TULIP 2 data are available later this year. TULIP 1 data will be presented at a future medical meeting.
A second trial, TULIP 2, compares a fixed dose of 300 mg of anifrolumab every four weeks against placebo for 373 patients. Topline results are expected later this year, according to the company.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Hereditary ATTR amyloidosis
Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.
EPNS 2019 Congress Highlights
The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology.
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Related Content
Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in phase III TULIP 2 trial. - AstraZeneca
AstraZeneca will tomorrow present detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine...
Added 26 days ago
Anifrolumab Phase III trial(TULIP 2) meets primary endpoint in systemic lupus erythematosus
AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic...
Added 3 months ago
EU approves new subcutaneous form of lupus treatment
The European Commission has approved a new subcutaneous formulation of Benlysta (belimumab), from GSK, as an add-on therapy in adult...
Added 2 years ago
FDA approves subcutaneous formulation of Benlysta (belimumab) for systemic lupus erythematosus- GlaxoSmithKline
The FDA has approved a new subcutaneous formulation of Benlysta (belimumab), from GlaxoSmithKline, for the treatment of adult patients with...
Added 2 years ago
Seven year data shows benefits of Benlysta (belimumab) in autoantibody-positive systemic lupus erythematosus- GlaxoSmithKline
GlaxoSmithKline has announced results from a 7-year safety and efficacy continuation study for Benlysta (belimumab) in patients with active, autoantibody-positive...
Added 3 years ago
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge.
Added 7 months ago
Trial of Tocilizumab in Giant-Cell Arteritis.
Background: Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on...
Added 2 years ago
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe...
Added 3 years ago
Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?
Objective: Worldwide prevalence estimates of systemic lupus erythematosus (SLE) range from 3 to 207 per 100,000, depending on region and...
Added 5 years ago
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-SC)
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
Added 9 years ago
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA. The study will consist of 2 parts...
Added 2 years ago
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
To assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Added 4 years ago
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
This study is to assess glomerular function before and during administration of stribild (STB; elvitegravir [EVG]/cobicistat [COBI]/emtricitabine [FTC]/tenofovir DF [TDF])...
Added 6 years ago
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet...
Added 6 years ago
Update of EULAR recommendations for the treatment of systemic sclerosis
These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
Added 1 year ago
BSR and BHPR guideline for the treatment of systemic sclerosis
This guideline will therefore provide advice and rationale for health professionals in making choices and decisions in the management of this disease.
Added 1 year ago
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice
These are the first EULAR recommendations providing up-to-date guidance for the role of imaging in the diagnosis and monitoring of patients with (suspected) LVV.
Added 1 year ago
The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome
This document aims to provide a pragmatic, practical guideline for the management of adults with pSS.
Added 1 year ago
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
The aim of this guideline was to produce recommendations for the management of adult lupus patients in the UK that cover the diagnosis, assessment and monitoring of lupus and the treatment of mild, moderate and severe active lupus disease...
Added 1 year ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.